CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 53 enrolled
Drug / intervention
pemetrexed +1 moredrug
Likely dose
pemetrexed 700 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00415168
NCT00415168Phase 2Completed
CompareCT.gov

Phase 2 Study of ALIMTA® (Pemetrexed) Plus Cisplatin as First-Line Treatment of Gastric Cancer

Eli Lilly and Company·interventional·Posted Dec 22, 2006·Updated Aug 17, 2010

In Brief

A Phase 2 clinical trial evaluating pemetrexed and cisplatin for Gastric Cancer. Completed, enrolled 53 participants across 6 sites.

Detailed Summary

Study H3E-MW- S108 is a multicenter, single arm, open-label Phase 2 study to determine the response rate of pemetrexed plus cisplatin in patients with Stage IV gastric cancer, not amenable to curative surgery, or recurrence after prior surgery, who have had no prior chemotherapy. It was planned to enroll approximately 50 patients who qualified for tumor response population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer
CountriesRussia
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 22, 2006
Enrollment StartDec 1, 2006
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 19.5 years ago

Interventions

pemetrexeddrug

700 milligrams/meters squared (mg/m2), intravenous (IV), every 21 days x 6 cycles

cisplatindrug

75 mg/m2, IV, every 21 days x 6 cycles